| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/14/2008 | US20080194650 Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents |
| 08/14/2008 | US20080194648 glutamate receptors agonists; especially to treat psychotic conditions, including schizophrenia and enhancement of cognition; N-{-2-[4-(6-fluoro-3-pyridinyl)phenyl]cyclopropyl}-2-propanesulfonamide |
| 08/14/2008 | US20080194645 N-[3-(4-chlorophenyl)-2-(3-pyridyl)-1-methylpropyl]-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide; obesity; antipsychotic agents; synergistic; cannabinoid receptor antagonists |
| 08/14/2008 | US20080194640 Optically Active Tetrahydronaphthalene Derivative |
| 08/14/2008 | US20080194636 Controlling insulin aminiopeptidase; cognition activators; induction labor and lactation; side effecxt reduction |
| 08/14/2008 | US20080194631 Concurrent antagonist of noradrenergic, n-Methylaspartic acid and serotonine receptors ; therapy for psychological disorders, nicotine addiction; alcoholism; sleep disorders; schizophrenia; hyperactivity |
| 08/14/2008 | US20080194628 Alzheimer's disease; cognition activators |
| 08/14/2008 | US20080194627 Aryl substituted pyridines and the use thereof |
| 08/14/2008 | US20080194625 Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| 08/14/2008 | US20080194624 Drug for Alzheimer's disease; cognition activators; strokes; down's disease; Parkinson's disease |
| 08/14/2008 | US20080194622 Antidepressants; anxiolytic agents;schizophrenia; cognition activators |
| 08/14/2008 | US20080194621 Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, pharmaceutical compositions and therapeutic use |
| 08/14/2008 | US20080194592 Organic Compounds |
| 08/14/2008 | US20080194589 Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists |
| 08/14/2008 | US20080194581 Pyrrole derivatives, intermediates therefor, preparation and therapeutic use thereof |
| 08/14/2008 | US20080194574 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases |
| 08/14/2008 | US20080194573 3-(Heteroaryl-Oxy)-2-Alkyl-1-Aza-Bicycloalkyl Derivatives As Alpha. 7-Nachrligands For TheTreatment Of Cns Diseases |
| 08/14/2008 | US20080194571 Acetylenic Piperazines as Metabotropic Glutamate Receptor Antagonists |
| 08/14/2008 | US20080194568 Pyridomorphinans, Pyridazinomorphinans and Use Thereof |
| 08/14/2008 | US20080194551 Acetylene Derivatives |
| 08/14/2008 | US20080194539 Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists |
| 08/14/2008 | US20080194538 Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor |
| 08/14/2008 | US20080194535 2-ethyl-hexanoic acid ((1S,4R,5S,8S,14R)-5-benzyl-4-hydroxy-18-methoxy-7-oxo-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10, 15(20),16,18-tetraen-8-yl)-methyl-amide; Alzheimer's Disease, Down's Syndrome; inhibitors of beta-secretase processing of amyloid precursor proteins |
| 08/14/2008 | US20080194530 Chemical Compounds |
| 08/14/2008 | US20080194524 Compounds For the Inhibition of Undesired Cell Proliferation and Use Thereof |
| 08/14/2008 | US20080194522 Substituted benzopyran-2-ones; competitive binding ligands for MAO inhibition; anxiolytic agents; neurodegenerative diseases, nervous system disorders; drug screening by comparing detectable changes in fluorescence when samples are oxidatively deaminated in the presence of a MAO |
| 08/14/2008 | US20080194519 Topiramate and a cyclodextrin in an injectible dosage form to be administered when oral administration has been interrupted; neuroprotectants; suitable for treating neonatal seizures |
| 08/14/2008 | US20080194501 Cyclic Bioisosters of Derivatives of a Purine System and Pharmaceutical Composition Based Thereon |
| 08/14/2008 | US20080194499 Solvent extraction of a plant extract from Centella asiatica; removing fatty substances and chlorophyll; purification by HPLC; concentrating the eluent to obtain pentacyclic terpenoid glycosides, preferably asiaticoside and madecassoside; obesity |
| 08/14/2008 | US20080194493 Compositions Containing D-Carnosine |
| 08/14/2008 | US20080194481 Albumin Fusion Proteins |
| 08/14/2008 | US20080193964 Compositions and methods for regulation of calcium-dependent signaling in brain |
| 08/14/2008 | US20080193574 Central nervous system disorders;Alzheimer's disease; using ginger oil |
| 08/14/2008 | US20080193567 Plant erxtracts; therapy for central nervous system disorders; learning enhancement; retardation; Alzheimer's disease; fragile x syndrome; psychological disorders; antidepressants; schizophrenia; anxiolytic agents; eating disorders; autism; bipolar disorders |
| 08/14/2008 | US20080193542 Ziprasidone mesylate or ziprasidone hydrochloride; nanoparticles less than 2000 nm; carrier; two surface stabilizers; crystallization inhibitors; polyvinylpyrrolidone, Pluronic surfactants; psychosis, schizophrenia; administration via intramuscular or subcutaneous injection |
| 08/14/2008 | US20080193526 Pharmaceutical Compositions Useful in the Treatment of Pain |
| 08/14/2008 | US20080193517 Polymer Conjugates of K-252A and Derivatives Thereof |
| 08/14/2008 | US20080193464 Identification of human autism susceptibility gene, which can be used for diagnosis, prevention and treatment of autism; invention discloses that the PRKCB1 gene of chromosome 16 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention |
| 08/14/2008 | US20080193444 Methods of suppressing LTP inhibition |
| 08/14/2008 | US20080193423 Small organic molecule regulators of cell proliferation |
| 08/14/2008 | US20080193415 HSA-free formulations of interferon-beta |
| 08/14/2008 | US20080193409 Compositions and Methods for Therapy or Prevention of Chemotherapy-Induced Neuropathy |
| 08/14/2008 | US20080193385 Compositions and methods for treating neuropathy |
| 08/14/2008 | CA2678193A1 Aza-bridged-ring compound |
| 08/14/2008 | CA2677995A1 Acylguanidine derivative |
| 08/14/2008 | CA2677838A1 Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
| 08/14/2008 | CA2677695A1 Use of flibanserin for the treatment of insomnia |
| 08/14/2008 | CA2677661A1 Tricyclic compounds |
| 08/14/2008 | CA2677493A1 Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
| 08/14/2008 | CA2677437A1 Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-ht7 receptor ligands |
| 08/14/2008 | CA2677241A1 Compounds that inhibit cholinesterase |
| 08/14/2008 | CA2677228A1 Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation |
| 08/14/2008 | CA2677026A1 An analgesic composition for neuropathic pain diseases containing n-acetylneuraminic acid |
| 08/14/2008 | CA2676139A1 Composition comprising terpene compounds and methods for inhibiting nerve transmission |
| 08/14/2008 | CA2675357A1 6-benzyl-2,3,4,7-tetrahydro-indolo [2, 3-c] quinoline compounds useful as pde5 inhibitors |
| 08/14/2008 | CA2674020A1 Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
| 08/13/2008 | EP1956079A1 Neural progenitor cells |
| 08/13/2008 | EP1956020A2 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity |
| 08/13/2008 | EP1956013A1 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition |
| 08/13/2008 | EP1956006A1 Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands |
| 08/13/2008 | EP1956004A1 Quinoline derivatives and their use as 5-HT6 ligands |
| 08/13/2008 | EP1956001A1 Pharmaceutical for use in the treatment of ureterolithiasis |
| 08/13/2008 | EP1955707A1 Pharmaceutical composition for prevention or treatment of neurogenic pain |
| 08/13/2008 | EP1955699A1 Use of flibanserin for the treatment of insomnia |
| 08/13/2008 | EP1955698A1 Preventive/therapeutic agent for alzheimer's dementia |
| 08/13/2008 | EP1954698A1 Spirocyclic compounds as hdac inhibitors |
| 08/13/2008 | EP1954693A1 Beta-secretase modulators and methods of use |
| 08/13/2008 | EP1954692A1 Heterocycle-substituted 3-alkyl azetidine derivatives |
| 08/13/2008 | EP1954689A1 N-substituted-1h-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same |
| 08/13/2008 | EP1954682A1 Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer s disease, neurodegeneration and dementia |
| 08/13/2008 | EP1954669A1 Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
| 08/13/2008 | EP1954652A2 An improved process for the preparation of armodafinil |
| 08/13/2008 | EP1954316A1 Methods of treating anxiety disorders |
| 08/13/2008 | EP1954289A2 Use of guanabenz and its derivatives for making drugs for treating cystic fibrosis and diseases related to a protein addressing deficiency in the cells |
| 08/13/2008 | EP1954283A2 Compounds for modulating trpv3 function |
| 08/13/2008 | EP1954268A2 Spirolactam bicyclic cgrp receptor antagonists |
| 08/13/2008 | EP1954260A2 Isocystene derivatives for the treatment of pain |
| 08/13/2008 | EP1954257A2 Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
| 08/13/2008 | EP1954135A2 Spirolactam aryl cgrp receptor antagonists |
| 08/13/2008 | EP1824837B1 Substituted n-sulfonylaminobenzyl-2-phenoxy acetamide compounds |
| 08/13/2008 | EP1603894B1 Pharmacologically active novel dauer pheromone compound for controlling aging and stress and method for isolating and characterizing the same |
| 08/13/2008 | EP1603532B1 Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders |
| 08/13/2008 | EP1590337B1 Acylaminothiazole derivatives, preparation method thereof and use of same as beta-amyloid peptide production inhibitors |
| 08/13/2008 | EP1539714B1 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
| 08/13/2008 | EP1505992B1 Method for reducing pain using oncolytic viruses |
| 08/13/2008 | EP1497250B1 Hyperforin derivatives, the use thereof and formulations containing them |
| 08/13/2008 | EP1496905B1 Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| 08/13/2008 | EP1494673B1 Compounds having unique cb1 receptor binding selectivity and methods for their production and use |
| 08/13/2008 | EP1489076B1 Cyclic hemiacetal derivative and use thereof |
| 08/13/2008 | EP1476200A4 Compositions and method for regulation of calcium-dependent signalling in brain |
| 08/13/2008 | EP1467979B1 Fused heterocyclic compounds and analogs thereof modulators of nuclear hormone receptor function |
| 08/13/2008 | EP1461042B1 Use of desoxypeganine for treating clinical depression |
| 08/13/2008 | EP1453501B1 N- aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity |
| 08/13/2008 | EP1435945B1 Topical migraine therapy |
| 08/13/2008 | EP1435874B1 Implantable devices for treatment of pain by delivery of fentanyl and fentanyl congeners |
| 08/13/2008 | EP1420782B1 Use of nefiracetam for treating post-stroke neurodegeneration |
| 08/13/2008 | EP1389098B1 Delivery of antipsychotics through an inhalation route |
| 08/13/2008 | EP1389097B1 Delivery of compounds for the treatment of parkinsons through an inhalation route |
| 08/13/2008 | EP1324761B1 Uridine therapy for patients with elevated purine levels |
| 08/13/2008 | EP1322309B1 High affinity small molecule c5a receptor modulators |